Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:TARA

Protara Therapeutics Q1 2026 Earnings Report

Protara Therapeutics logo
$5.41 -0.04 (-0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$5.51 +0.10 (+1.92%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Protara Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.36
Beat/Miss
N/A
One Year Ago EPS
N/A

Protara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protara Therapeutics Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Protara Therapeutics Earnings Headlines

One Protara Therapeutics Insider Raised Their Stake In The Previous Year
May 4 at 8:39 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/one-protara-therapeutics-insider-raised-101508094.html
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-na-ve-nmibc-patients-at-the-american-urological-association-annual-meeting-1036068262
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 5 at 1:00 AM  |  American Alternative (Ad)
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3282012/0/en/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-na%c3%afve-nmibc-patients-at-the-american-urological-association-annua.html
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
March 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/10/3252699/0/en/protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update.html
Protara reports encouraging phase 2 results for TARA-002 in bladder cancer study
February 25, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/protara-reports-encouraging-phase-2-results-for-tara-002-in-bladder-cancer-study/ar-AA1WYMTn
See More Protara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protara Therapeutics and other key companies, straight to your email.

About Protara Therapeutics

Protara Therapeutics (NASDAQ:TARA) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells. By engaging OX40, PTX-35 aims to amplify anti-tumor T-cell responses and promote durable immunity against viral antigens. The company has also advanced preclinical vaccine programs targeting high-grade cervical dysplasia driven by HPV-16 and HPV-18, with the goal of reducing the need for surgical intervention.

Headquartered in San Diego, California, Protara conducts early-stage clinical trials in North America and collaborates with academic research centers to explore combination regimens and next-generation immuno-oncology approaches. As a Nasdaq-listed company under the ticker TARA, Protara Therapeutics continues to build its pipeline through internal research and strategic partnerships aimed at addressing unmet needs in virus-associated oncology.

View Protara Therapeutics Profile
Earnings Tools